IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

Rhea-AI Summary

IGC Pharma (NYSE American: IGC) will participate in a fireside chat hosted by Ascendiant Capital Markets on February 18, 2026 at 1:00 p.m. ET. CEO Ram Mukunda and CCO Claudia Grimaldi will discuss Phase 2 CALMA trial progress, enrollment momentum, regulatory developments, and the company’s AI-driven precision medicine platform.

The presentation will also cover progress across IGC’s broader pipeline of disease-modifying Alzheimer’s candidates and management’s fiscal 2026 milestones and strategic priorities.

Key Figures

Event date: February 18, 2026 Event time: 1:00 p.m. ET Trial phase: Phase 2 +1 more

4 metrics

Event date February 18, 2026 Scheduled fireside chat with Ascendiant Capital Markets

Event time 1:00 p.m. ET Start time of fireside chat

Trial phase Phase 2 CALMA trial for IGC-AD1 in Alzheimer’s agitation

Fiscal year Fiscal 2026 Management to discuss milestones and strategic priorities

Market Reality Check

Price: $0.2520 Vol: Volume 272,848 vs. 20-day...

low vol

$0.2520 Last Close

Volume Volume 272,848 vs. 20-day average 433,972 (relative volume 0.63) suggests muted trading ahead of this event-driven update. low

Technical Shares at $0.252 trade below the $0.34 200-day MA, nearly 49.45% under the 52-week high and only 4.13% above the 52-week low.

Peers on Argus

While IGC is down 4.18%, several biotech peers also show declines (e.g., CASI -6...

While IGC is down 4.18%, several biotech peers also show declines (e.g., CASI -6.1%, ESLA -5.11%, LSB -20.62%). However, no peers appeared in the momentum scanner, and this scheduled fireside chat looks more company-specific than part of a coordinated sector move.

Historical Context

5 past events · Latest: Feb 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Equity research update	Positive	+3.8%	Broker reiterated Buy rating and set a $3.00 per-share target.
Feb 09	Clinical trial expansion	Positive	+1.2%	CALMA trial expanded into Colombia, boosting sites and enrollment progress.
Feb 02	Enrollment milestone	Positive	+1.5%	Reported reaching ~70% enrollment in Phase 2 CALMA Alzheimer’s agitation trial.
Jan 22	New trial site	Positive	+7.3%	Added New York trial site to strengthen CALMA execution and diversity.
Jan 12	New trial site	Positive	-0.1%	Richmond site added using hybrid model to expand access and enrollment.

Pattern Detected

Recent news, especially clinical trial progress and coverage updates, has more often seen positive price alignment, with only one noted divergence on a trial site expansion.

Recent Company History

Over the past month, IGC has focused on advancing its Phase 2 CALMA trial for IGC-AD1, adding new trial sites and reaching about 70% enrollment, which previously coincided with generally positive single-day moves (up to 7.31%). An equity research update on Feb 10, 2026 also saw a positive reaction. Today’s fireside chat centers on that ongoing clinical progress, AI-enabled precision medicine work, and upcoming fiscal 2026 milestones, fitting into a steady communication pattern around the CALMA program.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-12-03

An effective S-3/A resale shelf dated Dec 3, 2025 covers up to 978,235 shares for existing security holders; the company does not sell shares or receive proceeds under this registration, though it bears registration expenses. The shelf is effective, with at least one related prospectus supplement (424B5 on Jan 5, 2026) indicating active use of registered capacity.

Market Pulse Summary

This announcement highlights an upcoming investor-facing fireside chat where management plans to dis...

Analysis

This announcement highlights an upcoming investor-facing fireside chat where management plans to discuss Phase 2 CALMA progress, AI-driven precision medicine efforts, and fiscal 2026 priorities. It follows a series of clinical updates that previously moved the stock, including reaching about 70% enrollment and expanding trial sites. Investors may focus on clarity around timelines, resource needs after recent offerings, and how the broader Alzheimer’s pipeline complements IGC-AD1.

Key Terms

phase 2, precision medicine, alzheimer's disease, ai-driven, +1 more

5 terms

phase 2 medical

"its Phase 2 CALMA trial evaluating IGC-AD1 for agitation"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

precision medicine medical

"advancements in the Company's AI-driven precision medicine platform"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

alzheimer's disease medical

"for agitation associated with Alzheimer's disease, including enrollment momentum"

A progressive brain disorder that slowly erodes memory, thinking and the ability to carry out daily tasks as nerve cells are damaged and lost; symptoms typically worsen over years and can lead to severe impairment. Investors care because it drives a large, growing market for diagnostics, treatments and care services, but also carries high scientific, regulatory and commercial risk—similar to developing a complex new product that must pass difficult safety tests before it can reach patients.

ai-driven technical

"advancements in the Company's AI-driven precision medicine platform"

AI-driven describes products, services, processes or decisions that rely on artificial intelligence—software that detects patterns in data and makes predictions or choices without step-by-step human direction. For investors it signals potential for faster growth, lower operating costs or new revenue, but also new risks (model errors, data problems, regulatory limits); think of it like a smart thermostat that can save energy and money but can also misbehave if fed bad information.

disease-modifying medical

"its broader pipeline of disease-modifying Alzheimer's candidates."

A disease-modifying treatment alters the underlying course of an illness rather than only easing symptoms, like repairing a damaged foundation instead of just covering cracks. For investors, these therapies can lead to longer-lasting benefits, bigger market demand, and potential premium pricing or patent value because they may reduce long-term healthcare costs and change standards of care. Success or failure in this category can significantly affect a company's future revenue and valuation.

AI-generated analysis. Not financial advice.

POTOMAC, MD / ACCESS Newswire / February 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026, at 1:00 p.m. ET.

IGC Pharma's management will discuss recent clinical progress in its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease, including enrollment momentum and regulatory developments. The discussion will also cover advancements in the Company's AI-driven precision medicine platform and progress across its broader pipeline of disease-modifying Alzheimer's candidates. Management will provide perspective on upcoming milestones and strategic priorities for fiscal 2026.

To register for the fireside chat, please visit: Link

About IGC Pharma (dba IGC):

IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, and on Forms 10-Q filed with the SEC on August 14, 2025, and on November 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Contact Information:
Rosalyn Christian / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

When is IGC Pharma (IGC) scheduled to appear in the Ascendiant Capital Markets fireside chat?

The fireside chat is scheduled for February 18, 2026 at 1:00 p.m. ET. According to IGC Pharma, CEO Ram Mukunda and CCO Claudia Grimaldi will represent the company and discuss clinical and strategic updates.

What will IGC Pharma (IGC) discuss about the Phase 2 CALMA trial during the February 18 fireside chat?

IGC will discuss enrollment momentum and regulatory developments for the Phase 2 CALMA trial of IGC-AD1. According to IGC Pharma, management will provide updates on trial progress and near-term clinical milestones.

Will IGC Pharma (IGC) present updates on its AI-driven precision medicine platform at the Feb. 18 event?

Yes. Management will address advancements in the company’s AI-driven precision medicine platform. According to IGC Pharma, the discussion will link platform progress to development across its Alzheimer’s pipeline.

Who from IGC Pharma (IGC) will speak at the Ascendiant Capital Markets fireside chat?

CEO Ram Mukunda and CCO Claudia Grimaldi will participate in the fireside chat. According to IGC Pharma, both executives will discuss clinical updates, platform advancements, and fiscal 2026 priorities.

How can investors register for IGC Pharma's (IGC) Ascendiant fireside chat on February 18, 2026?

Investors can register via the event link provided by the company. According to IGC Pharma, registration details are available through the announced event link for the February 18 presentation.

What strategic topics will IGC Pharma (IGC) cover for fiscal 2026 during the fireside chat?

Management will outline upcoming milestones and strategic priorities for fiscal 2026. According to IGC Pharma, the discussion will prioritize clinical milestones, regulatory plans, and pipeline advancement strategies.